Chronic Diseases and Urban Health incorporating the TB case-control platform

Lead Research Organisation: London School of Hygiene & Tropical Medicine
Department Name: UNLISTED

Abstract

Changes in environment, nutrition, infrastructure, and epidemics has had profound impacts on the health of people worldwide. The impact in developing countries is even more pronounced due to lack of adequate health systems. The TB platform has demonstrated the importance of active cases finding, monitoring, follow up and analysis of exposed contacts on the overall health of the population. The evolution of the platform to chronic diseases and urban health will allow us to upscale this work and better evaluate the requirements for disease monitoring and prevention in The Gambia. The Chronic Diseases and Urban Health platform will support the planned work on non-communicable diseases and emerging health risks for the Unit. Information will be collected on environment, socio-economic status and risk factors related to lifestyle and will therefore work as a ‘targeted’ urban health surveillance system.

Technical Summary

The Chronic Diseases and Urban Health platform will support the planned work on non-communicable diseases and emerging health risks. It will evolve from the current TB Case Contact (TBCC) platform and include existing patients’ cohorts, e.g. rheumatic heart disease, who will be visited at least once a year to collect information on (among others) environment, socio-economic status and risk factors related to lifestyle. This platform will work as a ‘targeted’ urban health surveillance system and possibly develop into an urban HDSS.
The TB case-contact platform was established at MRC in 2001 and allows multi-disciplinary analysis of TB across the spectrum of infection and disease with over 2000 TB cases and 10000 close contacts enrolled to date. The platform has generated over 120 publications including epidemiological, clinical, microbiological, and immunological investigations and is currently recruiting participants for studies on post-TB lung health, a phase III TB vaccine trial, diagnostic and prognostic analysis of TB cases and their contacts and community screening of sub-clinical TB.
The CD&UH platform will include the existing cohorts of TB, chronic liver disease and rheumatic heart disease patients and patients with other chronic diseases such as hypertension, diabetes, and chronic respiratory diseases, e.g. asthma. Patients and their families will be visited at least once a year and data on demographic variables, environment, socio-economic status and risk factors related to lifestyle, health seeking behaviour, etc. will be collected. For each patient in the cohort, we will identify three neighbouring families for which we will collect the same information.

Publications

10 25 50

publication icon
Devoid I (2022) The household economic burden of drug-susceptible TB diagnosis and treatment in The Gambia. in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

publication icon
Nwongbouwoh Muefong C (2022) Neutrophils Contribute to Severity of Tuberculosis Pathology and Recovery From Lung Damage Pre- and Posttreatment. in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Related Projects

Project Reference Relationship Related To Start End Award Value
MC_UU_00031/1 01/04/2022 31/03/2027 £2,493,333
MC_UU_00031/2 Transfer MC_UU_00031/1 01/04/2022 31/03/2027 £2,493,333
MC_UU_00031/3 Transfer MC_UU_00031/2 01/04/2022 31/03/2027 £2,493,333
MC_UU_00031/4 Transfer MC_UU_00031/3 01/04/2022 31/03/2027 £2,015,400
MC_UU_00031/5 Transfer MC_UU_00031/4 01/04/2022 31/03/2027 £2,015,400
MC_UU_00031/6 Transfer MC_UU_00031/5 01/04/2022 31/03/2027 £2,015,400
MC_UU_00031/7 Transfer MC_UU_00031/6 01/04/2022 31/03/2027 £2,015,400
MC_UU_00031/8 Transfer MC_UU_00031/7 01/04/2022 31/03/2027 £2,015,400
MC_UU_00031/9 Transfer MC_UU_00031/8 01/04/2022 31/03/2027 £11,247,000
 
Description M72 Epi study 
Organisation Gates
Country United States 
Sector Private 
PI Contribution Site PI for a multi-site epi study
Collaborator Contribution Sponsor for the study
Impact None yet
Start Year 2022
 
Description TB Sequel II 
Organisation Ludwig Maximilian University of Munich (LMU Munich)
Country Germany 
Sector Academic/University 
PI Contribution MRC is one of the clinical sites and Prof Sutherland is the site-PI and work package lead for host immunological analysis
Collaborator Contribution LMU is the lead PI institution
Impact None yet as the project has only just begun
Start Year 2023
 
Description TBVAC-HORIZON 
Organisation London School of Hygiene and Tropical Medicine (LSHTM)
Country United Kingdom 
Sector Academic/University 
PI Contribution Site PI
Collaborator Contribution 30 other sites contributing to development of novel TB vaccines
Impact None to date
Start Year 2023